RBF Capital’s aTyr Pharma ATYR Stock Holding History

RBF Capital’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,000	Closed	-$15.6K	–	533
2026 Q1	$15.6K	Hold	20,000	–	–	﹤0.01%	491
2025 Q4	$15.7K	Hold	20,000	–	–	﹤0.01%	555
2025 Q3	$14.4K	Buy	+20,000	New	+$90.6K	﹤0.01%	576

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RBF Capital's ATYR Position: Q2 2026 in Review

RBF Capital sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 20,000 shares — an estimated $15.6K sold.

RBF Capital first reported a position in ATYR in Q3 2025 and held it in 3 quarters. The position peaked at $15.7K in Q4 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

RBF Capital reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
RBF Capital sold 20,000 aTyr Pharma shares in Q2 2026, an estimated $15.6K.
RBF Capital first reported a position in aTyr Pharma in Q3 2025 and held it in 3 quarters.
RBF Capital's aTyr Pharma position peaked at $15.7K in Q4 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.